Deep Intelligent Pharma
Deep Intelligent Pharma is a Singapore-based AI company that provides an AI-powered clinical trial and drug discovery platform for global pharmaceutical, biotech, and material science companies, automating protocol design, clinical operations, and regulatory submissions through a proprietary multi-agent ecosystem.
- Company typePrivate
- Founded2017
- HeadquartersSingapore, Singapore
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Deep Intelligent Pharma does
Deep Intelligent Pharma (DIP) is a Singapore-headquartered AI company that provides an integrated clinical research and drug discovery platform for pharmaceutical, biotechnology, and material science companies across China, Japan, and the United States. Founded in 2017 by AI scientists from global pharma giants, DIP operates three core AI products — AI CRO 6.0 (clinical research platform with tens of thousands of bionic workers running 24/7), Molecule Design Engine (mechanism-driven drug discovery platform), and Agent Matrix (multi-agent orchestration deployed since 2023) — plus a Protocol Rehearsal virtual clinical trials product launched in February 2026. The underlying technology integrates large-scale AI models with scientific computing to automate protocol design, data capture, biostatistics, medical writing, and regulatory submissions across NMPA, FDA, and PMDA jurisdictions, with reported performance gains of 12x in protocol design, 50x in clinical operations monitoring, and 15x in medical writing.
The company monetizes through enterprise B2B subscriptions and professional services, offering AI CRO full-stack solutions spanning preclinical research, clinical trials, and post-marketing research on a quote-based annual billing model. Its go-to-market is consultative direct enterprise sales targeting pharmaceutical companies, biotech firms, and material science enterprises across seven application domains (agrochemicals, batteries, semiconductors, alloys, polymers, high-standard metals, chemical materials). DIP has accumulated 1,000+ signed clients globally, achieved a stated 16% market share in the global LLM and agent-driven clinical CRO market per a 2026 Frost & Sullivan certification, and secured a zero-defect PMDA consultation pass (Immunorock) demonstrating regulatory execution. The company claims sustained profitability since 2021 and reached unicorn status at a multi-billion dollar valuation following a $50 million Series D in December 2025, followed by $60 million in February 2026 and $40 million in March 2026 — totaling $150 million raised within three months from investors including CDH Baifu/HongShan Capital, Trustar Capital, Xinding Capital, Jinyi Capital, Kaitai Capital, ZhenFund, and CITIC Capital.
Deep Intelligent Pharma firmographics
Firmographics- Name
- Deep Intelligent Pharma
- Legal name
- Deep Intelligent Particle (Beijing) Technology Co., Ltd.
- Website
- https://dip-ai.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Deep Intelligent Pharma is a Singapore-based AI company that provides an AI-powered clinical trial and drug discovery platform for global pharmaceutical, biotech, and material science companies, automating protocol design, clinical operations, and regulatory submissions through a proprietary multi-agent ecosystem.
- Ownership category
- akta.pro rank
Deep Intelligent Pharma industry classification
Industry- Product category
- AI Clinical Trial Software
- NAICS
- Software Publishers (5132), Custom Computer Programming Services (541511)
- SIC
- Services-Prepackaged Software (7372), Services-Computer Integrated Systems Design (7373)
- akta.pro primary industry
- Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
- akta.pro secondary industries
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management) (HDAEANAA)
Keywords
Where Deep Intelligent Pharma is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices3 records
Markets served
Deep Intelligent Pharma business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- AI CRO Services: Full-stack AI solutions for pharmaceutical companies covering preclinical research, clinical trials, and post-marketing research through subscription and usage-based engagement
- Technology Platform Licensing: Providing AI-powered core technology systems as foundational pharmaceutical infrastructure to enterprise clients
- Professional Services: Consulting and implementation services for AI-driven drug discovery and clinical trial optimization
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise solutions with custom pricing based on scope and engagement model |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Deep Intelligent Pharma product offering
Product offeringCore offering
Deep Intelligent Pharma builds AI-powered software platforms for pharmaceutical and biotech companies, integrating large-scale AI models with scientific computing across the drug development lifecycle. Its three core products — AI CRO 6.0 (clinical research platform), Molecule Design Engine (drug discovery), and Agent Matrix (multi-agent orchestration) — automate protocol design, clinical operations, data capture, biostatistics, regulatory submissions, and medical writing for pharmaceutical, biotech, and material science clients.
Product overview
Deep Intelligent Pharma operates a unified platform architecture with three core AI products: AI CRO 6.0 (clinical research platform), Molecule Design Engine (drug discovery platform), and Agent Matrix (multi-agent orchestration). These products work together as an integrated system, with Agent Matrix enabling autonomous orchestration of workflows across the clinical research and molecule design platforms. The company also offers Protocol Rehearsal as a virtual clinical trials capability. The platform serves both life sciences (drug development) and material science (batteries, semiconductors, agrochemicals) markets, providing end-to-end AI solutions from preclinical research through post-marketing studies.
Differentiator
Problem solved
Functional benefit
Brands
- AI CRO 6.0: Clinical Research Platform with tens of thousands of bionic workers running 24x7 to accelerate pipeline development.
- Molecule Design Engine
- Agent Matrix
Products and services
- AI CRO 6.0 Clinical research platform for pharmaceutical and biotech companies providing AI-assisted protocol design, intelligent data capture with real-time paperless workflows, AI-driven biostatistics and biomarker analysis, and automated CSR authoring. Targets enterprise pharma and biotech clients seeking to compress clinical timelines and reduce CRO manpower dependency.
- Molecule Design Engine Drug discovery platform using mechanism-driven AI simulation to enable precision targeting, compressing molecular screening to candidate confirmation from years to weeks. Designed for pharmaceutical R&D teams seeking AI-driven molecular design with deep understanding of biological mechanisms.
- Agent Matrix Multi-agent orchestration platform enabling matrix deployment of six agents collaborating in parallel 24x7 since 2023 for autonomous drug discovery and development workflows. Enables human-AI collaboration in life sciences and serves as the orchestration backbone for the company's other products.
- Protocol Rehearsal Virtual clinical trials product that conducts simulated clinical trials to predict enrollment outcomes before real patient enrollment, helping clinical teams de-risk protocol design and enrollment planning.
Quantifiable outcome
- 12x acceleration in protocol design (from 3 months to 1 week)
- +5 more outcomes
Companies that use Deep Intelligent Pharma
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Deep Intelligent Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature5 records
Deep Intelligent Pharma partnerships and signals
Strategic signalScale indicators9 records
Recent moves6 records
Expansion highlights6 records
Deep Intelligent Pharma competitors and assessment
Company assessmentDirect peers
- Insilico Medicine: AI-driven drug discovery and clinical development platform combining generative AI, multi-omics, and automated labs; directly comparable as an AI-native pharma R&D company serving pharma/biotech customers with similar end-to-end drug discovery and clinical workflows.
- Recursion Pharmaceuticals: AI-native biotech combining high-throughput wet-lab experimentation with machine learning for drug discovery; comparable in the AI-for-drug-development category and competes for similar pharma/biotech customers and partnerships.
- XtalPi: AI-driven drug discovery and materials science platform combining quantum physics, AI, and high-performance computing; closely comparable given dual life-sciences and materials-science focus and Asia-Pacific origin.
- Schrödinger: Physics-based computational chemistry and AI platform for molecular design and drug discovery serving global pharma; comparable as an enterprise software platform replacing traditional CRO/drug discovery workflows with AI-accelerated computation.
Emerging players
- Atomwise: AI-driven small molecule discovery platform using convolutional neural networks for hit identification; comparable in AI-driven drug discovery but with narrower focus on early-stage hit finding versus DIP's end-to-end clinical trial coverage.
- BenevolentAI: AI-driven drug discovery company using knowledge graphs and ML to identify novel targets and drug candidates; comparable in AI drug discovery category but focused on target identification rather than end-to-end clinical trial execution.
Broad incumbents
- Medidata (Dassault Systèmes): Enterprise clinical trial technology platform providing EDC, CTMS, eCOA and analytics to pharma/biotech; comparable as a clinical trial informatics vendor but embedded in much broader Dassault Systèmes 3DEXPERIENCE platform.
- IQVIA: Largest global CRO with embedded AI/analytics capabilities across clinical operations, real-world evidence, and commercial; competes for the same enterprise pharma customers but as a broad incumbent rather than AI-native specialist.
- ICON plc: Top-tier global CRO providing full-service clinical development with growing AI/data capabilities; comparable as a clinical CRO serving enterprise pharma, but with traditional labor-based delivery model rather than agent-driven execution.
Others
- Veeva Systems: Enterprise cloud software platform serving life sciences with CTMS, EDC, regulatory, and quality applications; adjacent peer as a software platform that pharma/biotech customers use to manage clinical trials, sharing the same buyer base as DIP.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Deep Intelligent Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Deep Intelligent Pharma leadership team
Management profileNumber of profiles
Profiles2 records
Deep Intelligent Pharma funding detail
Funding detailFunding overview
Funding rounds6 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Deep Intelligent Pharma M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Deep Intelligent Pharma
What does Deep Intelligent Pharma do?
Deep Intelligent Pharma builds AI-powered software platforms for pharmaceutical and biotech companies, integrating large-scale AI models with scientific computing across the drug development lifecycle. Its three core products — AI CRO 6.0 (clinical research platform), Molecule Design Engine (drug discovery), and Agent Matrix (multi-agent orchestration) — automate protocol design, clinical operations, data capture, biostatistics, regulatory submissions, and medical writing for pharmaceutical, biotech, and material science clients.
Is Deep Intelligent Pharma a public or private company?
Deep Intelligent Pharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was Deep Intelligent Pharma founded?
Deep Intelligent Pharma was founded in 2017. It employs 51 to 100 people.
Where is Deep Intelligent Pharma based?
Deep Intelligent Pharma is headquartered in Singapore, Singapore, in the Asia region.
How does Deep Intelligent Pharma make money?
Three revenue lines are on record. AI CRO Services are the primary driver. The others are technology Platform Licensing and professional Services.
Who are Deep Intelligent Pharma's main competitors?
Direct peers on record are Insilico Medicine, Recursion Pharmaceuticals, XtalPi and Schrödinger. Emerging players are Atomwise and BenevolentAI. Broad incumbents are Medidata (Dassault Systèmes), IQVIA and ICON plc. Veeva Systems is listed as an others.
Does Deep Intelligent Pharma have an API?
No public API is recorded for Deep Intelligent Pharma.
What industry is Deep Intelligent Pharma in?
Deep Intelligent Pharma's product category is AI Clinical Trial Software. Its primary akta.pro industry code is HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 5132 and its SIC code is 7372.